secwatch.observer — SEC 8-K summary
======================================

Issuer:     Liquidia Corp (LQDA)
CIK:        0001819576
Form:       8-K
Filed at:   2023-06-28T23:59:59+00:00
Accession:  0001104659-23-075439
Event type: m_and_a
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Liquidia exclusively licenses L606 (inhaled treprostinil) for N. America; $10M upfront, up to $215M milestones
--------------------------------------------------------------------------------

- Exclusive license from Pharmosa for development/commercialization of L606 in North America for PAH and PH-ILD.
- Upfront $10M funded via HCR revenue-interest financing amendment; total HCR draws now $42.5M of $100M facility.
- Milestone payments up to $215M for PAH/PH-ILD indications, plus $10M per additional indication/product; low double-digit royalties.
- L606 is a twice-daily sustained-release inhaled treprostinil; ongoing Phase 3 open-label study; NDA planned via 505(b)(2) pathway.
- Patent-litigation dependent $35M tranche remains unchanged; webcast held June 28, 2023 at 8:30 AM ET.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819576/000110465923075439/0001104659-23-075439-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819576/000110465923075439/tm2319810d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-075439

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer